Product: “More InSight: A Closer Look at the New AREDS2 Data and What It Means For Patients"
Top Line: Bausch + Lomb announced that data from the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which was recently published in JAMA Ophthalmology, will be reviewed and discussed among leading eyecare professionals during a live, complimentary webinar, "More InSight: A Closer Look at the New AREDS2 Data and What It Means For Patients" on Tuesday, Oct. 18, 2022, from 8:00-9:00 p.m. ET.
Close Up: The hour-long webinar is specifically designed to help eyecare professionals understand the new results and come away with knowledge of how it can be integrated into practice to support Age-related Macular Degeneration (AMD) patients. The session, which will be moderated by Paul Karpecki, OD, clinical director, Kentucky Eye Institute, will also spotlight clinical insights from Emily Chew, MD, chair, AREDS2 Study, NEI, and feature expert commentary from panelists Jeffry Gerson, OD, Grin Eyecare, Kansas City, Mo., and Rishi Singh, MD, president, Cleveland Clinic Martin North and South Hospitals, Cleveland.
"With the AREDS2 10 Year Follow-on Study, we now have more than two decades of research demonstrating the impact that a specific nutrient formula can have on patients with moderate to advanced AMD," said Dr. Chew. "The purpose of the 'More InSight' webinar is to discuss that impact - which further supports NEI's current recommendation of a specific combination of six nutrients, including lutein, zeaxanthin and antioxidants, and how doctors can implement these learnings in daily practice."
Joe Gordon, president, global consumer, surgical and vision care, Bausch + Lomb, commented, "Together with Drs. Chew, Gerson, Karpecki and Singh, we look forward to providing eyecare professionals with the opportunity to learn more about these latest research results as well as obtain insightful takeaways that can enhance their AMD practices and support the millions of people impacted by moderate to advanced AMD.
Vital Stats: To register for the 'More InSight' webinar, visit